Where the guideline stands	Insufficient evidence to recommend either way
Availability	Prescription
How long before you judge it	Unclear
Pregnancy	Avoid.
Sources behind this page	6, every one linked at the bottom

Flutamide for Acne at a glance. Recommendation strength and evidence certainty are separate axes under GRADE.

What it is

Flutamide is a nonsteroidal antiandrogen: it blocks the androgen receptor rather than lowering hormone levels. Androgens drive sebaceous glands to produce sebum, so blocking the receptor reduces oil production, which is the same general route by which spironolactone and combined oral contraceptives help acne. On the US label, flutamide is approved for one thing only: use in combination with an LHRH agonist to manage locally confined Stage B2-C and Stage D2 metastatic prostate carcinoma. It has never been approved for acne anywhere in that labelling, so any acne use is off-label. It is taken by mouth, usually divided across the day, and it requires scheduled blood tests for liver enzymes because of the risk described below.

What the evidence actually shows

The 2024 American Academy of Dermatology guideline places flutamide in its hormonal-agents insufficient-evidence statement: “Available evidence is insufficient to develop a recommendation on the use of oral corticosteroids, flutamide, or metformin for acne treatment.” That means the work group could not make a recommendation in either direction. It is not a recommendation against flutamide. The guideline’s only recommendation against anything is pneumatic broadband light added to adapalene 0.3%.

The reason is thin trial data, not a demonstrated failure. The most direct acne evidence is a pilot randomised trial by Adalatkhah and colleagues (Clinical, Cosmetic and Investigational Dermatology, 2011), which gave women with moderate acne either flutamide 250 mg daily for 21 days of each month or a cyproterone acetate-ethinyl estradiol pill, 32 per group, for six months. Twenty-four flutamide and 25 comparator patients completed follow-up. The endpoint was improvement from moderate to mild acne. In the per-protocol analysis the relative risk favoured flutamide, 1.33 (95% CI 1.03-1.72); the intention-to-treat analysis did not reach statistical significance. The authors concluded only that flutamide “appears to be more effective” in some respects and that confirmation in a larger trial was needed. Notably, the paper reports no liver function monitoring.

The hirsutism literature points the same way. A randomised study by Karakurt and colleagues (Advances in Therapy, 2008) compared flutamide 250 mg daily against spironolactone plus cyproterone acetate/ethinylestradiol in 29 women over six months. Ferriman-Gallwey scores fell in both arms, from 11.2 +/- 3.3 to 7.6 +/- 4.0 on flutamide and 9.9 +/- 1.9 to 7.1 +/- 2.0 on the comparator, with no significant difference between them. So the signal is real but small, and equivalent to safer alternatives.

How it is actually used

This is not a treatment to seek out, and the honest practical advice is to stop here. Flutamide has no acne approval, the acne trial evidence is one small pilot study, and the liver risk is not theoretical. The antiandrogen that actually carries a guideline recommendation for acne is spironolactone, a conditional recommendation supported by moderate-certainty evidence; combined oral contraceptive pills carry the same. If a prescriber ever raised flutamide, the label’s monitoring is not optional: serum transaminases before starting, flutamide not recommended if ALT exceeds twice the upper limit of normal, transaminases monthly for the first four months and periodically thereafter, liver tests at the first sign of nausea, vomiting, abdominal pain, fatigue, anorexia, flu-like symptoms, jaundice or right upper quadrant tenderness, and immediate discontinuation for jaundice or ALT above twice the upper limit of normal.

Safety and who should avoid it

The US label carries a boxed warning: “There have been postmarketing reports of hospitalization and rarely death due to liver failure in patients taking flutamide.” About half the reported cases occurred within the first three months. NIH LiverTox rates flutamide category A, a well known cause of clinically apparent liver injury, with aminotransferase elevations in up to 62% of patients on chronic therapy, marked elevations above five times normal in 3% to 5%, symptomatic injury with jaundice in 0.1% to 1%, and roughly three fatal cases per 10,000 treated. LiverTox states fatal cases have been reported in children and young women treated for hirsutism or acne. Avoid in pregnancy. For a condition of cosmetic severity, that trade is very hard to justify.

Commonly repeated: low-dose flutamide is safe for skin and hair conditions, because studies in women found no liver enzyme rises. What the evidence actually shows: those studies are real but far too small to settle it. Dikensoy and colleagues (Archives of Gynecology and Obstetrics, 2009) followed 214 women taking 125 mg or 250 mg daily for hirsutism over 12 months with liver enzymes at baseline and at 3, 6, 9 and 12 months, and saw no AST or ALT rise to 45 U/L or above. LiverTox agrees injury “may be partially dose related.” But a cohort of a few hundred cannot detect an event occurring in roughly one in a thousand to one in ten thousand people, and LiverTox records fatal cases specifically in young women treated for hirsutism or acne. Absence of signal in a small series is not evidence of safety.

Sources

Keep reading

See where this sits against every other acne treatment on the acne treatment evidence map, or check how it combines with another ingredient in the ingredient combination checker. For the guideline’s own wording on this, see the 2024 AAD guideline, recommendation by recommendation.

Not medical advice

This page reports what the published evidence says about a treatment. It is not a treatment plan and it cannot account for your skin, your other medications or your medical history. Nothing here has been reviewed by a clinician; see our editorial policy for what that means. Talk to a clinician before starting or stopping any prescription treatment.

Research, not medical advice. Every clinical claim above links to the guideline, systematic review, trial or drug label it came from, so you can check it yourself rather than take my word for it. It was researched and drafted with AI assistance by a non-clinician, and no dermatologist has reviewed it: this site does the reading, it doesn’t practise medicine. It can’t account for your circumstances either, so talk to a dermatologist or doctor about your own skin, especially before starting or stopping a prescription treatment.

Flutamide for Acne: Effective, and Rarely Worth the Risk